Quick Answer
X4 Pharmaceuticals, Inc reported Cash and Equivalents of $217.05 million for fiscal year 2025.
X4 Pharmaceuticals, Inc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $217.05M | +289.7% |
| 2024 | $55.70M | -43.9% |
| 2023 | $99.22M | -18.5% |
| 2022 | $121.72M | +48.8% |
| 2021 | $81.79M | +3.9% |
| 2020 | $78.71M | -37.6% |
| 2019 | $126.18M | +1451.3% |
| 2018 | $8.13M | -69.5% |
| 2017 | $26.68M | +76.0% |
| 2016 | $15.16M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $69.63M | -28.5% | +77.5% |
| June 30, 2025 | $39.22M | -73.4% | -2.6% |
| March 31, 2025 | $40.26M | -33.5% | -27.7% |
| December 31, 2024 | $55.70M | -43.9% | -42.8% |
| September 30, 2024 | $97.41M | -26.0% | -33.8% |
| June 30, 2024 | $147.22M | +7.9% | +143.4% |
| March 31, 2024 | $60.49M | -35.2% | -39.0% |
| December 31, 2023 | $99.22M | -18.5% | -24.6% |
- X4 Pharmaceuticals, Inc showed an increase of +289.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, X4 Pharmaceuticals, Inc’s cash and equivalents has grown by 1331.7% (from $15.16 million to $217.05 million).
- The most recent figure is from X4 Pharmaceuticals, Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: